Abstract
Fibromyalgia syndrome (FMS) is a chronic, idiopathic condition of widespread musculoskeletal pain, affecting primarily women. It is clinically characterized by chronic, nonarticular pain and a heightened response to pressure along with sleep disturbances, fatigue, bowel and bladder abnormalities, and cognitive dysfunction. The diagnostic criteria have changed repeatedly, and there is neither a definitive pathogenesis nor reliable diagnostic or prognostic biomarkers. Clinical and laboratory studies have provided evidence of altered central pain pathways. Recent evidence suggests the involvement of neuroinflammation with stress peptides triggering the release of neurosenzitizing mediators. The management of FMS requires a multidimensional approach including patient education, behavioral therapy, exercise, and pain management. Here we review recent data on the pathogenesis and propose new directions for research and treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 255-263 |
| Number of pages | 9 |
| Journal | Journal of Pharmacology and Experimental Therapeutics |
| Volume | 355 |
| Issue number | 2 |
| DOIs | |
| State | Published - Nov 1 2015 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.
ASJC Scopus Subject Areas
- Molecular Medicine
- Pharmacology
Fingerprint
Dive into the research topics of 'Fibromyalgia syndrome in need of effective treatments'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS